Progyny, Inc. (NASDAQ:PGNY) Stock Rated “Moderate Buy” by Wall Street Brokerages

Posted by Stanley Muller on Oct 23rd, 2026

Progyny, Inc. (NASDAQ:PGNY – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the thirteen research firms that are covering the firm, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $34.36.

Several research analysts have issued reports on PGNY shares. Truist Financial increased their price objective on Progyny from $33.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Canaccord Genuity Group set a $35.00 price objective on shares of Progyny in a research report on Friday, August 7th. KeyCorp increased their price objective on Progyny from $30.00 to $35.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Citigroup reissued an “outperform” rating on shares of Progyny in a report on Tuesday, September 8th. Finally, BTIG Research upped their target price on shares of Progyny from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, July 24th.

Get Our Latest Stock Report on Progyny

Progyny Trading Up 2.4%

Shares of PGNY stock opened at $29.12 on Friday. Progyny has a 12 month low of $16.10 and a 12 month high of $33.06. The company has a market capitalization of $2.23 billion, a P/E ratio of 31.65, a P/E/G ratio of 1.96 and a beta of 1.02. The stock has a 50 day moving average of $26.57 and a two-hundred day moving average of $25.85.

Progyny (NASDAQ:PGNY – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The company had revenue of $350.51 million during the quarter, compared to the consensus estimate of $349.05 million. During the same period last year, the firm earned $0.19 EPS. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. Sell-side analysts predict that Progyny will post 1.25 earnings per share for the current fiscal year.

Insider Buying and Selling at Progyny

In other news, EVP Allison Swartz sold 3,903 shares of Progyny stock in a transaction on Wednesday, September 23rd. The shares were sold at an average price of $26.10, for a total transaction of $101,868.30. Following the transaction, the executive vice president directly owned 75,816 shares of the company’s stock, valued at $1,978,797.60. This trade represents a 4.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Melissa B. Cummings sold 1,879 shares of Progyny stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $28.00, for a total transaction of $52,612.00. Following the transaction, the chief operating officer directly owned 66,496 shares in the company, valued at approximately $1,861,888. This represents a 2.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 17,282 shares of company stock valued at $475,790. Corporate insiders own 9.90% of the company’s stock.

Institutional Trading of Progyny

Several hedge funds have recently added to or reduced their stakes in PGNY. BlackRock Inc. bought a new position in Progyny during the second quarter worth about $334,426,000. Fort Washington Investment Advisors Inc. OH increased its stake in Progyny by 46.9% during the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock worth $45,734,000 after purchasing an additional 859,289 shares in the last quarter. Bank of America Corp DE increased its stake in Progyny by 75.3% during the 1st quarter. Bank of America Corp DE now owns 1,190,996 shares of the company’s stock worth $20,223,000 after purchasing an additional 511,609 shares in the last quarter. River Road Asset Management LLC increased its stake in Progyny by 13.9% during the 4th quarter. River Road Asset Management LLC now owns 687,824 shares of the company’s stock worth $17,663,000 after purchasing an additional 83,912 shares in the last quarter. Finally, William Blair Investment Management LLC acquired a new stake in Progyny during the 2nd quarter worth approximately $16,807,000. Institutional investors and hedge funds own 94.93% of the company’s stock.

About Progyny

(Get Free Report)

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.